GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Moderna Inc.
Moderna shares became world-famous thanks to its mRNA vaccine against COVID-19. The stock chart is a story of unprecedented scientific breakthrough and commercial success, followed by the discovery of new applications for this revolutionary technology in oncology and the treatment of rare diseases.
Share prices of companies in the market segment - Pharma infections
Moderna operates in the biotech segment, using its revolutionary mRNA platform to create vaccines and therapeutics. We classify it as an infectious disease pharmaceutical. The chart below shows the overall dynamics of this innovative, yet high-risk, sector.
Broad Market Index - GURU.Markets
Moderna is a biotech company that has become a global leader thanks to its revolutionary mRNA platform, which forms the basis of COVID-19 vaccines. Its industry weight earns it a spot in the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
MRNA - Daily change in the company's share price Moderna Inc.
The daily price change for Moderna, a pioneer in mRNA technology, is a measure of its high volatility and reaction to biotech news. The chart of these fluctuations is unspectacular, but it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma infections
Moderna, Inc. is a leading biotech company. This chart highlights the sector's extreme volatility. A comparison with MRNA, whose fate is closely tied to the success of its mRNA platform, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Moderna is a biotech company that rose to global fame thanks to its mRNA vaccine against COVID-19. The biotech sector is extremely volatile, and Moderna's story is a prime example. The chart below reflects the industry's average price movements, providing context for Moderna's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Moderna Inc.
Moderna, best known for its COVID-19 vaccine, has invested heavily in developing a portfolio of oncology and other mRNA-based drugs over the past year. Its year-over-year share price performance reflects the market's assessment of this long-term strategy.
Annual dynamics of market capitalization of the market segment - Pharma infections
Moderna, Inc., best known for its mRNA vaccine against COVID-19, is now using this revolutionary technology to create vaccines for other diseases and cancer treatments. Its stock performance is entirely dependent on the success of these new developments, making it one of the most volatile in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Moderna is a biotech company best known for its mRNA vaccine for COVID-19. Its current performance depends on its ability to apply its technology to vaccines for other diseases, such as influenza and cancer. It's a high-risk bet on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Moderna Inc.
Moderna's chart tracks the development of mRNA technologies. Following the success of its COVID-19 vaccine, monthly price fluctuations are now driven by news about clinical trials of new vaccines (influenza, RSV) and therapeutics, reflecting bets on future medical breakthroughs.
Monthly dynamics of market capitalization of the market segment - Pharma infections
This chart reflects the dynamics of the biotech sector, where Moderna has made a breakthrough. Its movements since the pandemic boom show how the company and the entire industry are trying to apply mRNA technology to the development of new vaccines and therapeutics.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Moderna, best known for its mRNA vaccine against COVID-19, is a biotech platform. Its performance is largely unrelated to overall market trends. Amid the fluctuations shown in the chart, Moderna's shares are anticipating news about clinical trials of its broad portfolio of mRNA drugs, from influenza to oncology, where every success is a breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Moderna Inc.
Moderna, a pioneer in mRNA technology, has been experiencing high weekly volatility. Its stock price has reacted sharply to news about clinical trials of new vaccines and therapeutics, as well as to changes in demand forecasts for its products.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Moderna is a pioneer in mRNA technology. Comparing its weekly performance with the pharmaceutical sector will reveal how investors value its platform. The chart clearly demonstrates how news about clinical trials of new vaccines (for cancer and flu) drives its stock price movement completely differently than that of traditional pharma companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Moderna, a pioneer in mRNA technology, exist in a world of their own, far removed from macroeconomic news. Their performance is determined by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
MRNA - Market capitalization of the company Moderna Inc.
Moderna's market capitalization chart is one of the most dramatic stories in modern pharmaceuticals. It illustrates the biotech startup's transformation into a global giant thanks to the success of its mRNA COVID-19 vaccine. The subsequent dynamics reflect the key question for investors: can the company replicate this success and transform its technology into a sustainable platform for new drugs.
MRNA - Share of the company's market capitalization Moderna Inc. within the market segment - Pharma infections
Moderna has become a global name thanks to its groundbreaking mRNA vaccine against COVID-19. The company's share of the pharmaceutical sector reflects not only the success of this vaccine but also investor confidence in the potential of the entire mRNA platform to treat other diseases. The chart below provides an indication of expectations for the biotech revolution spearheaded by Moderna.
Market capitalization of the market segment - Pharma infections
Moderna has become a global name thanks to its mRNA vaccine against COVID-19, but its technology has much broader potential. The chart below shows the overall market capitalization of the pharmaceutical sector. It helps us appreciate the scale of the industry Moderna is trying to revolutionize with its innovative platform.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart is one of the most compelling stories of the pandemic. Moderna's market capitalization soared on the success of its mRNA vaccine, creating a new giant in the pharmaceutical industry. Now, its line reflects the complex search for a new application for this revolutionary technology. It's a visual drama about scientific breakthroughs, market expectations, and the future of medicine.
Book value capitalization of the company, segment and market as a whole
MRNA - Book value capitalization of the company Moderna Inc.
Moderna's material foundation is its advanced mRNA vaccine manufacturing facilities, R&D laboratories, and the vast financial reserves accumulated in recent years. This is capital built on a scientific revolution. The chart below vividly illustrates how the commercial success of the COVID-19 vaccine has exponentially increased the biotech company's capital base.
MRNA - Share of the company's book capitalization Moderna Inc. within the market segment - Pharma infections
Moderna has become synonymous with mRNA technologies, and their production requires a unique infrastructure. The company's key assets are its cutting-edge facilities capable of rapidly producing mRNA vaccines at massive scale. The chart demonstrates its strategically important stake in this new and complex pharmaceutical manufacturing base.
Market segment balance sheet capitalization - Pharma infections
Moderna, a pioneer in mRNA technologies, is a capital-intensive business. This requires the ownership of advanced R&D centers and vaccine production facilities. The BCap_Seg chart for the biotech sector demonstrates that developing breakthrough technologies requires a robust scientific and manufacturing infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Moderna's balance sheet includes its advanced manufacturing facilities for creating mRNA vaccines and therapeutics, as well as its extensive patent portfolio. The company's assets are the physical and intellectual embodiment of the biotech revolution. The chart provides a glimpse into the material scale of this pharmaceutical innovator.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Moderna Inc.
Moderna's balance sheet consists of its factories and capital. But its market valuation at its peak was tens of times higher, as the market valued its revolutionary mRNA platform, which can create vaccines and cures for a multitude of diseases, rather than these. The chart is an attempt by investors to glimpse the future of medicine.
Market to book capitalization ratio in a market segment - Pharma infections
Moderna, a pioneer in mRNA technology, is valued based on the potential of its scientific platform for developing vaccines and drugs. Despite its relatively small physical assets, its market capitalization is enormous. The chart illustrates investors' faith in the company's future breakthroughs.
Market to book capitalization ratio for the market as a whole
Moderna is a biotech company renowned for its mRNA vaccine. Its core value is its revolutionary technological platform, capable of creating new drugs. This leads to a colossal gap between its market value and book value, as investors evaluate future potential rather than current tangible assets.
Debts of the company, segment and market as a whole
MRNA - Company debts Moderna Inc.
Moderna, a biotech company, uses debt to fund expensive research and clinical trials. This debt allows the company to invest in its revolutionary mRNA platform without diluting its equity. This chart shows how the company is using its leverage to achieve the next medical breakthroughs.
Market segment debts - Pharma infections
Moderna, known for its mRNA vaccine against COVID-19, is at the forefront of biotechnology. Developing platform technology requires massive investment. The company's leverage, following the vaccine's windfall profits, is an important indicator of its strategy. This chart shows how Moderna manages its capital to fund future breakthroughs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Moderna Inc.
Moderna, known for its mRNA vaccine, operates in a biotech industry that requires significant investment in R&D. This chart shows how the company finances the development of new drugs. Low debt levels following the vaccine's success may indicate a strong financial position and the ability to independently fund future research.
Market segment debt to market segment book capitalization - Pharma infections
Moderna, known for its mRNA COVID-19 vaccine, operates at the forefront of biotechnology. Developing new mRNA-based drugs requires colossal and risky investments. The chart shows how the company's debt burden compares to the overall financial capacity of the entire innovative pharmaceutical industry.
Debt to book value of all companies in the market
Moderna, a biotech innovator, finances its expensive mRNA research, including through debt. This chart allows us to assess the significance of these investments in the future of medicine on an economic scale, comparing the company's debt to the total market capitalization of all sectors.
P/E of the company, segment and market as a whole
P/E - Moderna Inc.
Moderna, a pioneer in mRNA technology, achieved a breakthrough with its COVID-19 vaccine. This chart shows how much the market values each dollar of Moderna's profit. Its dynamics reflect investors' faith in the future success of its scientific platform. The sharp decline in this indicator in the past was due to the colossal revenue from the vaccine, while the current values reflect expectations for new developments.
P/E of the market segment - Pharma infections
Moderna, a pioneer in mRNA technology, operates in a sector where valuation depends on future breakthroughs. This chart shows the average valuation for the biotech industry. It emphasizes that Moderna's valuation depends less on current profits than on investor confidence in its scientific platform compared to other biotechs.
P/E of the market as a whole
Moderna has become known worldwide for its mRNA vaccine against COVID-19. The company is a pioneer in this revolutionary technology with potential to treat numerous diseases. This chart shows the overall risk appetite. For Moderna, whose valuation is based on future breakthroughs, high market optimism is vital to funding its ambitious research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Moderna Inc.
Moderna is a biotech company best known for its mRNA vaccine against COVID-19. This chart shows market expectations for the future of its mRNA platform. The dynamics reflect investors' confidence in the success of vaccines against influenza, cancer, and other diseases after the pandemic.
%20P%2FE%20Moderna%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Moderna-Inc.&v=1772598913060 "Chart of the company's future (projected) P/E Moderna Inc.")
Future (projected) P/E of the market segment - Pharma infections
Moderna has become world-renowned for its mRNA vaccine against COVID-19. This chart reflects average profitability expectations in the pharmaceutical sector. It allows investors to assess the potential of Moderna's mRNA platform for developing vaccines for other diseases and drugs, beyond its success in fighting the pandemic.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772598913075 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Moderna, Inc. is a biotech company that rose to global fame thanks to its mRNA vaccine against COVID-19. This chart demonstrates investors' appetite for risk and innovation. For a company at the forefront of the biotech revolution, it reflects the market's confidence in the potential of its platform to create new drugs and vaccines in the future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772598913079 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Moderna Inc.
Moderna has gained worldwide recognition for its mRNA vaccine against COVID-19. The financial results shown in this chart demonstrate the unprecedented commercial success of this technology. The trend reflects not only the vaccine's revenue but also the potential of the entire mRNA platform to create new drugs against various diseases in the future.
Profit of companies in the market segment - Pharma infections
Moderna has become a global name thanks to its pioneering mRNA platform, which formed the basis of one of the leading COVID-19 vaccines. The company continues to explore the potential of mRNA for treating other diseases. This chart illustrates how biotech breakthroughs can radically change the profitability of the entire pharmaceutical industry and create new markets.
Overall market profit
Moderna, best known for its mRNA vaccine against COVID-19, is a pioneer in biotechnology. Its future success depends on its ability to develop new drugs based on this platform. The company represents an innovative sector that requires significant investment, which becomes more accessible during periods of strong economies and rising corporate profits, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Moderna Inc.
Moderna is a biotech company best known for its mRNA vaccine against COVID-19. The earnings forecast shown in this chart shows analysts' expectations for future vaccine sales and, more importantly, the success of its mRNA platform in developing treatments for other diseases, including cancer and rare diseases.
%20profit%20of%20the%20company%20Moderna%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Moderna-Inc.&v=1772598913139 "Graph of future (projected) profit of the company Moderna Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
Moderna has become a global name thanks to its mRNA vaccine against COVID-19. The company is a pioneer in mRNA technology and is developing vaccines against other infectious diseases and cancer. This chart shows the revenue forecast for the infectious pharmaceuticals sector, allowing one to assess how Moderna is leveraging its platform for future growth after the pandemic.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772598913156 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
Moderna is a biotech company best known for its mRNA vaccine against COVID-19. Its future depends on the success of developing new vaccines and therapeutics. The overall state of the economy, reflected in this chart, influences the willingness of governments and investors to fund innovative biotechnologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772598913168 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Moderna Inc.
Moderna, a pioneer in mRNA technology, rose to prominence thanks to its COVID-19 vaccine. This chart illustrates how the market is pricing its revenue following the pandemic boom. The metric's dynamics reflect the uncertainty and enormous potential of its mRNA platform for developing vaccines and treatments for other diseases.
P/S market segment - Pharma infections
Moderna, Inc. is a biotechnology company that gained worldwide recognition for developing one of the first mRNA vaccines against COVID-19. Its business model is based on the potential of mRNA technology for the development of vaccines and therapeutics. This chart reflects how investors view Moderna's scientific platform and future revenue prospects in the pharmaceutical industry.
P/S of the market as a whole
Moderna rose to global prominence with its mRNA vaccine against COVID-19, demonstrating the power of its technology platform. The company is at the forefront of the biotech revolution. This chart helps us understand the market's expectations for biotech companies capable of creating breakthrough products and how investors assess their future revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Moderna Inc.
Moderna, a pioneer in mRNA technology, has become world-renowned for its COVID-19 vaccine. This chart shows how the market values the company relative to its future sales. It reflects investors' high expectations for the success of its entire mRNA platform, including vaccines for influenza, cancer, and other diseases.
%20P%2FS%20Moderna%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Moderna-Inc.&v=1772598913288 "The graph of the company's future (projected) P/S Moderna Inc.")
Future (projected) P/S of the market segment - Pharma infections
Moderna has become a global name thanks to its innovative mRNA platform, which forms the basis of one of the leading COVID-19 vaccines. The company continues to explore the potential of this technology for other diseases. This chart reflects investor expectations for its future sales, both from the vaccine and from new developments, compared to other biopharma companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772598913317 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
Moderna, a pioneer in mRNA technology, rose to prominence with its COVID-19 vaccine. The company's future revenue depends on the success of its platform in developing new vaccines and therapeutics. This general guidance chart for mRNA is not a direct driver. The company's success is determined by scientific breakthroughs and global health needs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772598913375 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Moderna Inc.
The dynamics in this chart are a clear example of the impact of biotechnology on global healthcare. For Moderna, this is largely determined by global sales of its COVID-19 vaccine. Future performance will depend on the success of other drugs developed using its innovative mRNA platform.
Sales of companies in the market segment - Pharma infections
Moderna, Inc. is a biotech company best known for its mRNA vaccine against COVID-19. Its future growth depends on the success of other drugs in development based on the same technology. This chart illustrates how the potential of mRNA technology to treat infectious diseases and cancer could impact Moderna's financial performance and that of the industry as a whole.
Overall market sales
Moderna has gained worldwide recognition for its mRNA vaccine against COVID-19. The company is at the forefront of the biotech revolution. Its success in developing new vaccines and therapeutics reflects the potential of innovation in healthcare, a sector that plays an increasingly important role in the global economy and impacts overall well-being.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Moderna Inc.
Moderna, a pioneer in mRNA technology, has become world-renowned for its COVID-19 vaccine. Its future sales forecast reflects expectations not only for its vaccines but also for its entire pipeline, including treatments for cancer and rare diseases. This chart offers a glimpse into the future of one of the most innovative biotech platforms.
%20sales%20of%20the%20company%20Moderna%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Moderna-Inc.&v=1772598913493 "Schedule of future (projected) sales of the company Moderna Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
Moderna, Inc. has become a global name thanks to its mRNA vaccine against COVID-19. The outlook for the infectious disease pharmaceutical sector reflects expectations for new technologies. It helps us understand whether Moderna can leverage its revolutionary platform to develop vaccines and drugs against other diseases, meeting high expectations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772598913543 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Moderna is a biotech company best known for its mRNA vaccine against COVID-19. Its future success depends on the development of new vaccines and therapeutics. Demand for its products is driven by healthcare needs, not economic cycles. However, the overall economic situation, as reflected here, influences government funding for pandemic preparedness.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772598913556 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Moderna Inc.
Moderna, the biotech company best known for its mRNA COVID-19 vaccine, shows the impact of a single blockbuster on its financial performance in this chart. The company's profitability soared with the success of the vaccine, and its growth will now depend on its ability to commercialize other mRNA-based treatments.
Market segment marginality - Pharma infections
Moderna, a pioneer in mRNA technology, has become world-renowned for its COVID-19 vaccine. This chart shows the average profitability in the biotech industry. The success of its platform technology and the potential to create new vaccines and therapeutics enable the company to achieve exceptionally high profitability compared to the industry average.
Market marginality as a whole
Moderna, Inc. is a biotech company best known for its mRNA vaccine against COVID-19. This chart shows average profitability. Compared to this, Moderna is a story of how a single revolutionary platform can generate enormous revenue, but long-term profitability depends on the ability to apply this technology to create new successful treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Moderna Inc.
Moderna has revolutionized medicine with its mRNA platform, especially during the COVID-19 pandemic. This chart vividly illustrates the company's explosive growth. A dramatic increase in scientists, engineers, and manufacturing personnel was necessary to scale up research, production, and global distribution of the vaccine at an unprecedented rate.
Share of the company's employees Moderna Inc. within the market segment - Pharma infections
Moderna has become a global name thanks to its groundbreaking mRNA vaccine against COVID-19. This chart illustrates the scientific breakthrough it has made and the potential it has garnered. It reflects the rapidly growing pool of leading biologists, chemists, and clinical researchers working on its revolutionary mRNA technology.
Number of employees in the market segment - Pharma infections
Moderna gained worldwide recognition for its mRNA vaccine against COVID-19, a breakthrough for the technology as a whole. This chart illustrates the explosive growth in the biotech sector fueled by the pandemic. The company quickly hired thousands of scientists and specialists, demonstrating the industry's ability to quickly respond to global threats.
Number of employees in the market as a whole
Moderna, a pioneer in mRNA technology, has gained worldwide recognition for its COVID-19 vaccine. In addition to vaccines, the company is developing therapeutics. Overall economic stability, reflected in the chart, is important for public and private funding of cutting-edge biotech research, which is essential for Moderna's future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Moderna Inc. (MRNA)
Moderna gained worldwide recognition for its breakthrough mRNA vaccine against COVID-19. This chart tells the story of how a single technology can generate colossal value. The astronomical market capitalization per employee at peak moments suggests that the market valued not so much current sales as the potential of the entire mRNA platform for the future of medicine.
%20of%20the%20company%20Moderna%20Inc.%20(MRNA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Moderna-Inc.-MRNA&v=1772598913773 "Chart of market capitalization per employee (in thousands of dollars) of the company Moderna Inc. (MRNA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Moderna, best known for its mRNA vaccine, is a biotech company focused on platform research. Their business is science and intellectual property. This chart shows the average salary per employee in the pharmaceutical sector. Comparisons help understand how the market values Moderna's technology platform and its revenue-generating potential per scientist.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772598913808 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Moderna has become world-renowned for its mRNA vaccine against COVID-19. It's a biotech company whose value is based on the potential of its innovative platform. This chart demonstrates an extremely high valuation per employee, as a small team's scientific breakthrough can lead to the creation of products with global demand and multibillion-dollar sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772598913847 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Moderna Inc. (MRNA)
Moderna is a biotech company that rose to global fame thanks to its mRNA vaccine against COVID-19. It's a business built on a cutting-edge scientific platform. This metric can be extremely high. It reflects how a breakthrough technology (mRNA), developed by a team of scientists, can generate billions of dollars in profits with a relatively small staff (compared to pharma giants).
%20Chart%20Moderna%20Inc.%20(MRNA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Moderna-Inc.-MRNA&v=1772598913856 "Company Profit Per Employee (in thousands of dollars) Chart Moderna Inc. (MRNA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Moderna is a biotech company that has become a giant thanks to "mRNA technology" (the Covid vaccine). This chart shows the benchmark for "Pharma" (Infections). Average profit per employee in this sector is the most volatile in the world. The benchmark "skyrocketed" on one product (the vaccine), and now it's falling. It's a "one-hit wonder."
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772598913880 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Moderna is a biotech company that rose to global fame thanks to its mRNA vaccine against COVID-19. Its platform enables the rapid development of new drugs. This chart illustrates the potential of biotech: a single breakthrough product, based on years of research, can generate billions of dollars in revenue, resulting in astronomical profits per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772598913912 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Moderna Inc. (MRNA)
Moderna, a pioneer in mRNA technologies, demonstrated their power during the pandemic. This chart shows the commercial success of their innovative platform. Astronomical revenue per employee during peak years reflected the global demand for their vaccine. It's an example of how breakthrough science can generate colossal revenue with a relatively small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Moderna-Inc.-MRNA&v=1772598913929 "Sales chart per company employee Moderna Inc. (MRNA)")
Sales per employee in the market segment - Pharma infections
Moderna, a pioneer in mRNA technology, has grown into a global company. In biotech, revenue per employee can be volatile, depending on the success of its drugs. This chart shows how effectively their research team and manufacturing staff convert scientific breakthroughs into commercial sales, especially compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Moderna, Inc. is a biotech company that rose to global fame thanks to its mRNA platform technology, which led to the creation of a COVID-19 vaccine. This chart shows the enormous revenue the company can generate when its R&D platform takes off. It reflects the effectiveness of investing in science: a small team of scientists can create a product worth billions of dollars.
Short shares by company, segment and market as a whole
Shares shorted by company Moderna Inc. (MRNA)
Moderna gained worldwide recognition for its mRNA vaccine against COVID-19. The company is now using this technology to develop vaccines against influenza, RSV, and cancer. This chart shows bearish bets. These bears are betting that COVID vaccine revenues will decline sharply, and that new drugs in development will either fail in trials or fail to offset the decline.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Moderna-Inc.-MRNA&v=1772598914086 "Short Shares Chart for the Company Moderna Inc. (MRNA)")
Shares shorted by market segment - Pharma infections
Moderna, a pioneer in mRNA technology, is seeking new growth opportunities after the pandemic. This chart shows the total volume of short positions across the entire biotech sector. It reflects overall investor skepticism. If this figure is high, it could indicate that the market doubts the ability of the entire industry (including Moderna) to quickly launch new blockbusters or is concerned about regulatory pressure.
Shares shorted by the overall market
Moderna (MRNA), famous for its mRNA vaccine, is now using this platform to create other vaccines and drugs. This chart shows the overall level of fear. When pessimism rises, investors flee risky biotechs. MRNA is a bet on a scientific breakthrough. In "calm" times, people believe in this, but in "stormy" (fearful) times, investors are risk-averse.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Moderna Inc. (MRNA)
Moderna is a pioneer in mRNA technology, known for its COVID vaccine. **This chart** measures the response to binary events. Successful Phase 3 data for their new mRNA vaccine (for cancer or flu) could trigger explosive growth and euphoria, pushing **This chart** above 70. A trial failure would send **This chart** into panic zone (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Moderna-Inc.-MRNA&v=1772598914262 "RSI 14 indicator chart for the company's stock Moderna Inc. (MRNA)")
RSI 14 Market Segment - Pharma infections
Moderna (MRNA) isn't a "single vaccine." It's a platform company betting on mRNA technology. Post-COVID, their goal is to prove that mRNA treats flu, cancer, and other diseases. This chart shows the overall sentiment in the biotech sector. It helps us understand: is MRNA oversold due to a R&D failure or is there a general cooling toward the entire sector?
RSI 14 for the overall market
Moderna (MRNA), a pioneer in mRNA technology, rose to global fame thanks to its COVID-19 vaccine. The company is now exploring new applications for its platform. This market climate indicator is important. MRNA is a volatile stock. During moments of euphoria, investors believe in new breakthroughs. During panic, they see only falling vaccine revenues and flee the stock.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MRNA (Moderna Inc.)
Moderna is a biotech company whose mRNA platform enabled the creation of one of the leading COVID-19 vaccines. Now their business is racing for the next blockbuster. This chart shows the analysts' average 12-month target. It reflects their sales expectations for updated vaccines and their assessment of their R&D portfolio (influenza, oncology).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MRNA-Moderna-Inc.&v=1772598914389 "A chart showing analyst consensus forecasts for the expected stock price. MRNA (Moderna Inc.)")
The difference between the consensus estimate and the actual stock price MRNA (Moderna Inc.)
Moderna is a biotech company that rose to global fame thanks to its mRNA vaccine against COVID-19. Their goal now is to prove that this technology can treat other diseases (influenza, cancer, and rare diseases). This chart shows how much analysts believe in their R&D pipeline post-COVID. It reflects the gap between the consensus forecast and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MRNA-Moderna-Inc.&v=1772598914403 "A chart showing the difference between the consensus forecast and the actual stock price. MRNA (Moderna Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Moderna is a revolutionary biotech company whose mRNA platform enabled the creation of a highly effective COVID vaccine. The company is now targeting influenza, cancer, and rare diseases. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe mRNA technology will revolutionize treatment.
Analysts' consensus forecast for the overall market share price
Moderna is a biotech company best known for its mRNA vaccine. They are now exploring applications of this technology in oncology and other fields. Market expectations, as shown in this chart, influence risk appetite. After the pandemic, Moderna is a risky R&D project that investors are reluctant to fund during downturns.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Moderna Inc.
Moderna is a biotech company that, thanks to its revolutionary mRNA COVID-19 vaccine, transformed itself from an R&D startup into a global giant. This chart reflects their complex transition. Its dynamics reflect the market's assessment of their ability to use the billions from the vaccine to develop new mRNA treatments (for cancer and influenza) and avoid becoming a one-hit wonder.
AKIMA Market Segment Index - Pharma infections
Moderna is a pioneer in mRNA technology; a biotech company that (together with BioNTech) created a breakthrough vaccine (Spikevax) and is now using this platform to create flu and cancer vaccines. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Moderna's futuristic mRNA platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Moderna is a biotech company that rose to global fame thanks to its breakthrough mRNA vaccine (Spikevax) for COVID-19. The company is now using this technology for oncology and other vaccines. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to overall economic trends.
